A seasoned leader, Sean has over 20 years of industry experiences, successfully brought multiple drugs to the market, led post M&A integration between Merck and Schering-Plough, and managed global R&D and manufacturing teams. Sean served in various leadership positions over his 15-year career with Merck & Co. and then with Luye Pharma, where he was most recently the Group VP, Head of International R&D and CEO of GeneLeap, a Luye subsidiary focusing on nucleic acid therapeutics. Sean holds a PhD from Ohio State University and an MBA from Wharton.

Jason is responsible for preclinical R&D, technology development, and pipeline strategy and execution. He has broad scientific knowledge in DAs including oncology, immunology, neurology, and infectious diseases, with modalities and MOAs covering small molecule, antibodies, ADCs, mRNA, AAV, and oligos. Jason is experienced in drug discovery and development with 7 drug candidates in phase I-III stages of clinical trials and contributed to one marketed drug. He has also engaged in business development and alliance management with academia, pharma, and biotech. Jason has a PhD in immunology from NYU with Dr. Dan Littman as advisor, a second PhD in chemistry from PUMC with Dr. Xiaotian Liang as advisor. Jason also conducted postdoc research at Yale and Harvard.

Bilikallahalli Muralidhara (Murali), PhD, oversees Global Manufacturing, CMC strategy, and Supply Chain at RVAC. Murali has over 18 years of technical & leadership experience in CMC & Manufacturing and has contributed to eight approved biologic & vaccine products, with. progressive leadership roles in big pharma (Pfizer, AstraZeneca, GSK) and in mid-size biotech (Ultragenyx & Acceleron). He has worked with DNA and m-RNA/SAM vaccines & therapeutics, oligonucleotides & delivery technologies. He has also published 46 research articles, made 40 international presentations and currently serves on the Editorial Boards of Drug Discovery Today, mAbs and Vaccines & Vaccinations. Murali has a Ph.D in biochemistry & biophysics from the University of Mysore (IND) and conducted postdoc research at Kyoto (JPN) & Rice (US) Universities.

Dr. Mohamed ElSayed is the Chief Technology Officer at RVAC. He is an accomplished leader with over 25 years of experience spanning academic, biotechnology, and pharmaceutical organizations. He has deep expertise in the development of innovative delivery technologies for nucleic acids, biologics, bioconjugates, and small molecules. Prior to RVAC, Dr. ElSayed held positions of increasing responsibilities at Eli Lilly & Company where he established the Oral Peptides Delivery Platform and led the discovery and preclinical development of multiple oral biologics. He is a recognized expert in the development of nucleic acid therapies. Earlier in his career, Dr. ElSayed was a tenured professor at the University of Michigan and served as an advisor for multiple biopharmaceutical companies; he received a Ph.D. in Pharmaceutical Sciences from the University of Maryland in Baltimore.